Einführung
Thymosin Alpha‑1 is a 28‑amino acid peptide originally isolated from thymic tissue and has since become a foundational molecule in immunological research. Its highly conserved sequence and well‑characterized role in adaptive immunity make it a valuable tool for studying T‑cell development, cytokine networks, and the interplay between innate and adaptive responses. Laboratories across academia and industry rely on this peptide to probe mechanisms of immune regulation and to develop sensitive detection systems for thymosin‑like molecules.
We supply Thymosin Alpha‑1 raw material synthesized entirely via solid‑phase peptide synthesis (SPPS), a method that allows precise control over the amino acid chain and eliminates contamination from biologically sourced materials. Every production run is monitored with strict process controls to deliver a product that meets the consistency demands of long‑term research programs. The result is a synthetic peptide with batch‑to‑batch reproducibility in both purity and activity profiles, suitable for experiments that require minimal variability.
Our lyophilized Thymosin Alpha‑1 is prepared for research institutions and pharmaceutical companies that require bulk amounts for in vitro and in vivo investigations. Whether a laboratory needs 5 mg for a pilot study or several grams for large‑scale screening, the raw material can be packaged under conditions that protect the peptide’s stability. For buyers sourcing a consistent, well‑documented supply of this key immunomodulatory peptide, our release specifications and supporting analytics provide the assurance necessary for rigorous experimental work.
Produktspezifikationen
Each batch of Thymosin Alpha‑1 raw material is subjected to orthogonal analytical methods to confirm identity, purity, and structural integrity. The primary release criterion is purity, which is ≥98% as measured by reversed‑phase high‑performance liquid chromatography (RP‑HPLC). This level ensures that impurities that could interfere with sensitive assays are kept below the threshold where they might influence experimental outcomes. The chromatogram and integration data are reported in the Certificate of Analysis (CoA) that accompanies every order.
The molecular formula of Thymosin Alpha‑1 is C129H215N33O55, corresponding to a monoisotopic molecular weight of 3108.24 g/mol. The peptide sequence, Ac‑SDAAVDTSSEITTKDLKEKKEVVEEAEN‑OH, is validated by mass spectrometry, typically electrospray ionization (ESI‑MS) or matrix‑assisted laser desorption/ionization (MALDI‑TOF). The measured mass must match the theoretical value within a narrow tolerance, confirming that the 28 residues are correctly assembled and that no significant truncations or deletions are present.
The product is supplied as a sterile, non‑pyrogenic lyophilized powder. The synthesis process uses exclusively chemical building blocks and reagents, meaning the final material is free from animal‑derived components. This attribute is critical for studies where adventitious agents or lot‑to‑lot biological variability could confound results. The lyophilized form, sealed under an inert atmosphere, preserves the peptide’s native structure and minimizes oxidation or hydrolysis during storage.
Packaging Options
Standard single‑vial sizes are 5 mg, 10 mg, 25 mg, 50 mg, and 100 mg of net peptide content. Each vial is precision‑filled to within ±10% of the target mass, and the exact fill weight is stated on the label and CoA. These pre‑measured amounts allow researchers to reconstitute directly to desired stock concentrations without bulk handling, reducing the risk of contamination and peptide loss.
For projects that require larger quantities, bulk packaging is available in increments starting at 1 g. Bulk material can be supplied in multiple vials, single larger containers, or as a single‑use aliquot format tailored to the user’s workflow. Custom packaging with specific vial labels, bar coding, or double‑bagging for export is also offered. Such flexibility reduces transfer steps and aligns the product presentation with good laboratory practice and inventory management systems.
All packaging is performed in a class 10,000 cleanroom environment. Vials are sealed under dry nitrogen and then crimped to maintain integrity during transit. For stability, each lot is tested after packaging to verify that the filling and sealing processes have not introduced moisture or degraded the peptide. Requests for novel packaging configurations are evaluated on a case‑by‑case basis, with typical lead times provided upon inquiry.
Anwendungen in der Forschung
Thymosin Alpha‑1 serves as a critical tool in immunological studies focused on T‑cell biology. Researchers have documented its ability to influence the maturation and differentiation of thymocytes, and it is frequently employed to explore how peptide signals modulate the expression of surface markers such as CD3, CD4, and CD8. By introducing the peptide into co‑culture systems, labs can dissect the signaling pathways that govern T‑cell receptor complex assembly and positive selection.
A second major application is as a reference standard in enzyme‑linked immunosorbent assays (ELISA) and related immunoaffinity methods. Because Thymosin Alpha‑1 elicits a specific antibody response, it is used to generate calibration curves that quantify endogenous thymosin levels in tissue lysates, plasma, or conditioned media. In radioimmunoassays and competitive ELISA formats, the synthetic peptide provides a benchmark that ensures inter‑assay comparability and method validation.
Additionally, the peptide is employed in cell‑culture experiments that examine immune cell activation and proliferation. Mitogen‑ or antigen‑stimulated lymphocyte cultures are often supplemented with Thymosin Alpha‑1 to investigate its influence on the secretion of cytokines such as interleukin‑2, interferon‑gamma, and tumor necrosis factor‑alpha. These functional assays contribute to a broader understanding of how the thymic peptide shapes immune homeostasis and the early response to pathogens.
Cell Culture and Assays
In protein‑based detection workflows, Thymosin Alpha‑1 is frequently used as a positive control. For Western blotting, a known amount of the peptide is loaded alongside cellular extracts to confirm that the detection antibody recognizes the target and that the electrophoretic mobility of the synthetic protein matches the endogenous form. In flow cytometry, intracellular staining protocols may include the peptide as a blocking reagent or as a competition control to validate primary antibody specificity for T‑cell markers.
The peptide is also suitable for in vitro functional assays that evaluate lymphocyte responses. Mixed lymphocyte reactions or antigen‑specific T‑cell activation tests can include graded concentrations of Thymosin Alpha‑1 to observe shifts in proliferation indices, measured by CFSE dilution or [3H]‑thymidine incorporation. Such experiments help clarify the peptide’s context‑dependent effects on both helper and cytotoxic T‑cell subsets without implying any physiological outcome beyond the controlled experimental environment.
More specialized investigations utilize the peptide to study dendritic cell (DC) maturation and antigen presentation. When added to monocyte‑derived DC cultures, the peptide may alter the expression of MHC class II and co‑stimulatory molecules, which can be quantified by flow cytometry. These translational models are widely valued in vaccine research and immunotoxicology, where understanding how a synthetic thymic peptide modulates the interface between innate and adaptive immunity is of central interest.
Qualitätskontrolle und Dokumentation
Every production lot undergoes a complete analytical panel to verify identity, purity, and composition. Reversed‑phase HPLC is the primary purity assay; any single impurity detected must be below 2% of the total peak area. Mass spectrometry confirms the correct molecular weight and primary structure. In addition, amino acid analysis (AAA) quantifies the molar ratios of constituent amino acids, ensuring that the synthetic protein matches the expected composition. These data are reviewed by an independent quality unit before release.
A Certificate of Analysis (CoA) is issued with each shipment. The CoA includes the lot number, the net peptide content, the purity percentage, the observed mass, and the recommended storage conditions. It also lists the methods and specifications used for release. This document serves as a traceable record that can be archived to fulfill institutional documentation requirements or to support publications describing work with the peptide.
The entire manufacturing and quality assurance process is governed by an ISO 9001:2015 certified quality management system. This ensures that standard operating procedures are followed for synthesis, purification, lyophilization, packaging, and analytical testing. Regular third‑party audits confirm that the facility maintains control over critical quality attributes and that non‑conformances are addressed through corrective and preventive actions. Customers may request a copy of the facility’s current ISO certificate during the purchasing process.
Handling and Storage Recommendations
To preserve long‑term stability, the lyophilized product should be stored at –20 °C or below, protected from moisture and light. Vials that have not been opened can be kept under these conditions for a minimum of 24 months from the date of manufacture without significant loss of peptide integrity. After opening, the vial should be handled in a dry, inert environment whenever possible to minimize the introduction of atmospheric water vapor.
For reconstitution, sterile water for injection or a suitable biological buffer (e.g., sterile PBS, pH 7.4) is recommended. The choice of diluent should be based on the intended downstream application, as some buffers may interfere with certain assays. Once the peptide is dissolved, the solution is best used immediately. If this is not feasible, the reconstituted product should be aliquoted into single‑use portions and stored at –80 °C. Repeated freeze‑thaw cycles must be avoided, as they can lead to aggregation and loss of functional activity.
Data from accelerated stability studies indicate that the peptide maintains its specified purity for extended periods when stored in the lyophilized state at the recommended temperature. However, it is the responsibility of the end user to establish local stability protocols if the product is reformulated or used in a manner that differs from these recommendations. For any inquiry regarding the suitability of a specific diluent or storage condition, our technical support team can provide guidance based on existing internal data.
Bestellinformationen
The minimum order quantity is one vial containing 5 mg of Thymosin Alpha‑1 raw material. Standard catalog sizes are held in inventory and can usually be dispatched within 3–5 business days after receipt of a purchase order. Pricing is tiered based on volume, so bulk orders of 1 g or more may be eligible for reduced per‑milligram costs. For very large quantities or scheduled deliveries spanning multiple quarters, customized commercial agreements can be discussed.
Custom requests, such as unusual packaging formats, dedicated labeling, or additional quality tests, require additional processing time. The estimated lead time for these orders is provided during the quotation phase, typically ranging from two to four weeks depending on complexity. Our sales team will confirm feasibility, cost, and delivery schedule after reviewing the specific technical requirements.
International shipping is available to a wide range of destinations. The product is shipped with cold packs when required by the transit duration and ambient conditions. All export and import documentation is prepared to comply with applicable regulations, but the buyer is responsible for verifying any import permits or licensing needed in their country. Our terms and conditions of sale define liability, payment terms, and delivery obligations. For a formal quotation or to discuss a prospective order, please contact our sales department directly.
Nur für Forschungszwecke. All products described are intended solely for laboratory research and development. They are not for use in humans or animals for any other purpose. No information provided should be interpreted as suggesting a therapeutic, veterinary, or diagnostic application.
Nur für Forschungszwecke. Nicht zur Anwendung am Menschen oder bei Tieren bestimmt.
